Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

Summary

We want to learn if dasatinib will make triple negative breast cancers smaller. We also hope that we can learn more about what makes triple negative breast cancers grow. We believe this information will help us to predict which patients will benefit from taking this drug or other drugs like it. This study is a "neoadjuvant study", which means that it is only open to women who have not had any treatment for their breast cancer. Neoadjuvant studies allow the study doctor to look at how the cells in your cancer change after taking the study medication. This will help us to understand whether or not dasatinib is an effective treatment for breast cancer. It will also help us to learn more about triple negative breast cancer and how to treat it.

Timeline

Start

2008-12

Primary completion

2011-02

Completion

2011-02

Outcome

Outcome not reported

Stopped: “terminated due to futility after interim analysis”

Drugs

Indications